The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $17.2 up 1.18% from its previous closing price of $17.0. In other words, the price has increased by $1.18 from its previous closing price. On the day, 1.17 million shares were traded. NRIX stock price reached its highest trading level at $17.39 during the session, while it also had its lowest trading level at $16.68.
Ratios:
For a deeper understanding of Nurix Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On October 21, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $24.
On March 17, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $16.Leerink Partners initiated its Market Perform rating on March 17, 2025, with a $16 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 24 ’25 when Ring Christine sold 37,600 shares for $17.07 per share. The transaction valued at 641,697 led to the insider holds 50,897 shares of the business.
CHRISTINE RING bought 37,600 shares of NRIX for $630,176 on Nov 24 ’25. On Nov 03 ’25, another insider, van Houte Hans, who serves as the Chief Financial Officer of the company, sold 6,284 shares for $12.56 each. As a result, the insider received 78,931 and left with 37,592 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 1743550848 and an Enterprise Value of 950052096. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.83 while its Price-to-Book (P/B) ratio in mrq is 3.55. Its current Enterprise Value per Revenue stands at 11.352 whereas that against EBITDA is -3.663.
Stock Price History:
The Beta on a monthly basis for NRIX is 1.84, which has changed by -0.22207147 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $23.00, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is 51.39%, while the 200-Day Moving Average is calculated to be 49.02%.
Shares Statistics:
For the past three months, NRIX has traded an average of 1.45M shares per day and 1645460 over the past ten days. A total of 101.37M shares are outstanding, with a floating share count of 99.81M. Insiders hold about 1.53% of the company’s shares, while institutions hold 82.45% stake in the company. Shares short for NRIX as of 1763078400 were 14076725 with a Short Ratio of 9.68, compared to 1760486400 on 13868490. Therefore, it implies a Short% of Shares Outstanding of 14076725 and a Short% of Float of 15.640001.
Earnings Estimates
The stock of Nurix Therapeutics Inc (NRIX) is currently being evaluated by 13.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.84, with high estimates of -$0.61 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.48 and -$3.39 for the fiscal current year, implying an average EPS of -$3.11. EPS for the following year is -$3.48, with 13.0 analysts recommending between -$2.13 and -$4.46.
Revenue Estimates
For the next quarter, 16 analysts are estimating revenue of $16.72M. There is a high estimate of $22.5M for the next quarter, whereas the lowest estimate is $13.8M. A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $108.78M, while the lowest revenue estimate was $70.4M, resulting in an average revenue estimate of $85.25M. In the same quarter a year ago, actual revenue was $54.55M
